- 专利标题: Liquid oral formulations for tadalafil
-
申请号: US17403282申请日: 2021-08-16
-
公开(公告)号: US11382917B2公开(公告)日: 2022-07-12
- 发明人: Jinal Pandya , Sandip P. Mehta , Manish Umrethia , Jayanta Kumar Mandal , Hiren Pansuriya
- 申请人: LIQMEDS WORLDWIDE LIMITED
- 申请人地址: GB Middlesex
- 专利权人: LIQMEDS WORLDWIDE LIMITED
- 当前专利权人: LIQMEDS WORLDWIDE LIMITED
- 当前专利权人地址: GB Middlesex
- 代理机构: Merchant & Gould P.C.
- 代理商 Daniel R. Evans
- 优先权: IN201721046640 20171226,IN201821012438 20180402
- 主分类号: A61K31/519
- IPC分类号: A61K31/519 ; A61K31/4985 ; A61K47/10 ; A61K9/08
摘要:
The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.
公开/授权文献
- US20210369717A1 LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS 公开/授权日:2021-12-02
信息查询
IPC分类: